Parkinson's patients in Brazil turn to a movement practice known as capoeira to ease symptoms
That changed after she began attending a capoeira class in downtown Rio de Janeiro especially designed for people with the neurodegenerative illness.
Capoeira is a movement practice that originated within the large enslaved communities in Brazil, where nearly 5 million kidnapped Africans disembarked during the transatlantic slave trade that started in the 16th century.
It is considered both a martial art and a dance, combining ritual, exercise, spirituality and music.
'Capoeira gives me freedom to work on my body. What I can do. What I can't do. So I can have balance and a more comfortable life,' Teles de Freitas said during a recent class.
Practiced for centuries by Afro-Brazilians, it has since become popular around the world. UNESCO recognized the practice in 2014 as Intangible Cultural Heritage.
The project started in 2018 with physical therapist Rosimeire Peixoto, 60, who at that point had been attending capoeira classes herself for over a decade.
After working with many patients with Parkinson's, she said she became convinced that introducing them to capoeira may help alleviate some of their symptoms.
Parkinson's has a range of different symptoms, and along with difficulties in balancing, some common ones include slowness of movement, tremors and stooped posture. Patients can also experience anxiety, depression, sleeping disorders and nausea.
'I had the idea after reading an article that said alternating both hands when using a cell phone stimulates both hemispheres of the brain,' she said. 'And as a physiotherapist treating neurological patients, I was lacking exercises that would motivate them.'
Peixoto's project was dubbed "Parkinson na ginga' — or 'Parkinson's in the swing' — a reference to the first fluid, rhythmic step that capoeira practitioners learn. She now holds classes twice a week in the Progress Foundry, a sprawling cultural center in downtown Rio next to a famed white 18th century aqueduct and surrounded by palm trees.
Capoeira helps improve balance, coordination and strength, with music loosening up tense bodies, Peixoto says.
'There is a lot happening in a capoeira circle. They feel the vibration, the energy, they pay attention to the music and to the partner to dodge blows' and to themselves, she said.
During a recent class, Peixoto walked among the students, placing a gentle hand on a back here and there to help with balance, patiently repeating demonstrations and offering words of encouragement.
Antônio de Azevedo, who was diagnosed with Parkinson's disease a few years ago, said he could hardly stand before. But since he started practicing capoeira, his stability returned.
'It's the best thing that's ever happened to me,' he said while he attended a capoeira class with around 10 other people, all with Parkinson's.
Peixoto tries to make the classes a fun and social event — she often suggests a group samba dance at the end of the class, and regularly brings a cake to share.
Teles de Freitas, the retired teacher, says that she loves the camaraderie among the class.
'We are there for one another,' she said. 'Feeling and conversing with friends gives strength.'
She remembers how when she got her diagnosis, she left the doctor's office crying, terrified of the future.
'Today I'm smiling," she said. "I'm managing to live. I'm managing to interact with other people. I'm managing to be happy.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 hours ago
- Yahoo
AstraZeneca's Tagrisso combo shows OS improvement in Phase III NSCLC trial
AstraZeneca's Tagrisso (osimertinib) combined with pemetrexed and platinum-based chemotherapy has shown improvement in overall survival (OS) for those with first-line locally advanced or metastatic epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC). According to the final analysis of the randomised Phase III trial, FLAURA2, it demonstrated a consistent survival benefit, echoing interim OS outcomes and building upon the earlier reported longest median progression-free survival (PFS) data for this setting. The combo showed OS improvements in the open-label, global, multi-centre trial when compared against Tagrisso as a single agent for this patient group. Subjects in the trial received 80mg of Tagrisso daily in oral tablet form, combined with a chemotherapy regimen. The chemotherapy included pemetrexed at a dosage of 500mg/m² and either cisplatin at 75mg/m² or carboplatin (AUC5) administered every three weeks for a total of four cycles. After completing the cycles, the treatment continued with Tagrisso alongside maintenance doses of pemetrexed, also given every three weeks. A total of 557 subjects were enrolled in the trial in more than 150 centres across over 20 nations, including in Asia, Europe, South America, and the US. PFS is the primary endpoint of the trial. The combination therapy's safety profile remained manageable, aligning with known profiles of the individual medicines. According to the company, the trial recorded higher adverse event rates in the combination arm, attributed to expected chemotherapy-related effects. Discontinuation rates due to adverse events remained low. These findings are set to be presented at an upcoming medical meeting and will be communicated to global regulatory bodies. AstraZeneca oncology haematology R&D executive vice-president Susan Galbraith said: 'These exciting overall survival results add to the extensive evidence supporting Tagrisso as the backbone therapy in EGFR-mutated lung cancer, demonstrating that Tagrisso plus chemotherapy can significantly extend survival in the first-line advanced setting, in addition to prior trials showing survival benefits as monotherapy in both early stage and advanced disease.' More than 80 nations, including the European Union (EU), the US, Japan, and China, have currently approved Tagrisso + chemotherapy based on the FLAURA2 trial data. In 2023, AstraZeneca reported positive outcomes from the ADAURA Phase III trial of Tagrisso in the adjuvant treatment of individuals with Stage IB, II, IIIA EGFRm NSCLC. "AstraZeneca's Tagrisso combo shows OS improvement in Phase III NSCLC trial" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio


Medscape
14 hours ago
- Medscape
Role of GLP-1 Drugs in Psoriasis and PsA Is Debated
BOGOTÁ, Colombia — Most dermatologists and rheumatologists agree that GLP-1 receptor agonists (GLP-1 RAs), such as liraglutide, semaglutide, and tirzepatide, powerful antidiabetes and weight-loss drugs, have the potential to help some patients with psoriasis and psoriatic arthritis (PsA). Besides mitigating obesity, an established risk factor for psoriasis and PsA, GLP-1 drugs have shown promise in improving psoriasis symptoms and are associated with a lower risk for cardiovascular events, for which people with psoriasis and PsA are at increased risk. Some researchers predict that the drugs will prove to have immunomodulatory effects and become an important addition to current treatments for psoriasis and PsA, even in patients without obesity or diabetes. At the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2025 Annual Meeting and Trainee Symposium, investigators with the GRAPPA dove into hours' worth of discussions and debates about a class of drugs whose emergence Artie Kavanaugh, MD, professor of medicine at the University of California, San Diego, described as a possible 'watershed moment' for the field, akin to the advent of biologic therapies in the 1990s. But with evidence still sparse in patients with psoriatic disease and ancillary concerns about access, cost, patient selection, and physician confidence in prescribing, there was little agreement as to how, whether, or when these drugs should be integrated into clinical practice. A GLP-1 Pioneer Endocrinologist Daniel J. Drucker, MD, professor in the Department of Medicine's Division of Endocrinology, University of Toronto, Ontario, Canada, who discovered some key biological actions of the hormone GLP-1 in the 1980s and '90s, kicked off the conference with a video presentation affirming GLP-1 RAs potential as immunoregulatory agents with anti-inflammatory activity beyond their well-documented effects on body weight. In a 2023 trial of semaglutide in patients with obesity who did not have diabetes, Drucker noted prevention of cardiovascular events and death was seen as independent of weight loss. Similarly, Drucker said, a recent trial in people with metabolic liver disease saw improvements associated with semaglutide that were independent of weight loss. With psoriasis and PsA, randomized controlled trial evidence has yet to support weight-loss independent improvements in symptoms. However, this may soon change: In two separate trials, Eli Lilly is studying a combination of tirzepatide and the interleukin-17A antagonist ixekizumab in patients with overweight or obesity and psoriasis or PsA. The trials will wrap up next summer. Results from trials of GLP-1 inhibitors in nonobese populations, including cohorts of people with Alzheimer's disease, stand to shed further light on their anti-inflammatory effects outside the context of weight loss, Drucker said. 'These medicines are diversifying. We're going to see a wave of new molecules and new indications to treat inflammation,' he predicted, including that of skin, joints, and bone. Still, Drucker cautioned, the drugs 'are not magic bullets, and each condition will need to be assessed on its own.' Real-World Experience From Latin America In a subsequent talk, Enrique Soriano, MD, head of rheumatology at the Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, presented a real-world perspective from Latin America, where GLP-1 drugs are approved in most countries for diabetes or obesity — but still not easy to access and far from becoming a routine part of any rheumatologist's or dermatologist's daily practice. 'We all know that obesity increases the risk of developing psoriatic arthritis in psoriasis patients,' Soriano said — and that weight loss can decrease that risk. 'We also know that treatment response is lower in PsA patients with obesity,' he said. 'But the question for us is whether this drug [class] can improve symptoms and inflammation in our patients and whether this improvement, if it happens, is related to the weight loss or is an independent effect.' Soriano presented a retrospective review from his institution's service of 6800 patients with psoriasis (mostly mild) and 488 with PsA. In each group, just over 1% of patients were taking a GLP-1 RA for obesity, diabetes, or both. While acknowledging the limitations of his study's retrospective design, Soriano noted that 'there was no report of any improvement or change in the skin involvement, and there was also no record of any change in their joint symptoms after starting these drugs.' Soriano also conducted a survey of rheumatologists across several countries in Latin America and found that under a third said that they had encountered a patient whom they thought could benefit from the addition of a GLP-1 drug, while fewer than 10% said that they would feel confident prescribing one. More than half said that if they did think a patient could benefit, they would refer that person to a specialist, such as an endocrinologist. Dermatologist Describes Current Data as 'Weak' Anthony Fernandez, MD, PhD, director of medical and inpatient dermatology at the Cleveland Clinic, Cleveland, praised GLP-1 RAs as 'fascinating medications' with 'a very attractive adverse event profile.' Fernandez cited studies dating back over a decade in which use of these medications has been shown to improve psoriasis. 'And we have some data to suggest that the mechanism…is not entirely related to weight loss. In fact, there's data to support that these medications affect psoriasis-relevant immune pathways. So, in that way, they share similarities with many of the systemic medicines that we already prescribe to treat psoriasis.' Still, Fernandez cautioned, 'The data right now is really weak,' limited to small studies and randomized trials enrolling mostly men. While a few patients in these studies saw dramatic improvements in psoriasis after starting these drugs, 'the reality is that most have, at best, a modest improvement,' he said, 'certainly nowhere near the improvement we are used to seeing' from targeted synthetic disease-modifying antirheumatic drugs (tsDMARDs) and biologic DMARDs (bDMARDs). Moreover, he said, some patients enrolled in the studies were effectively treatment naive. 'That raises a critical question about whether or not a patient [on ts- or bDMARDs] would actually see any further improvement adding GLP-1 RAs,' he said. Fernandez said he thought that dermatologists can safely prescribe and manage GLP-1 therapies. The bigger question is whether they should. 'My opinion is no,' he concluded. 'There will be rare patients who are obese and or have type 2 diabetes and either fail or have a contraindication to all the great systemic medicines we already have available to us. And in those patients, a trial of a GLP-1 RA would seem to be reasonable. But personally, I think we need much, much better data for recommendations concerning general use by dermatologists.' During a question-and-answer period after Soriano's and Fernandez's presentations, other physicians shared their experiences and practical concerns about insurance approvals, referrals, and whether most dermatologists and rheumatologists were simply too busy to manage all the comorbidities of chronic immune-mediated disease for their patients. Some shared anecdotes about patients whose disease had improved after treatment with GLP-1 RAs, including in the absence of other systemic therapies. Patients Intrigued — but Share Clinician's Caution At the same session, Suzanne Grieb, PhD, a patient research participant (PRP) with GRAPPA and assistant professor at Johns Hopkins University, Baltimore , presented results from a survey of her fellow GRAPPA PRPs about their experiences and interests regarding GLP-1 drugs. None of the 11 respondents reported having been prescribed the medications. 'The majority of us described our psoriatic disease as mostly manageable with our current treatment,' Grieb, who has PsA, told the conference. However, that did not mean they weren't curious about GLP-1s. Grieb's survey revealed that while all participants were aware of the importance of exercise and healthy weight in disease management, many continued to struggle with both. Few reported having spoken with their providers about specific interventions. While three respondents expressed interest in taking GLP-1s, they were uncertain whether they would be able to access them. Patients 'are interested in GLP-1s' impact on our psoriatic disease, but also on other elements of our health, thinking more holistically [about] the benefits that could be achieved through these medications,' Grieb said. But the respondents in her survey also reported concerns about adding medications and 'the potential for having to take this medication for the rest of our lives.' In an interview after her presentation, Grieb elaborated on her personal perspective. 'I don't meet the requirement for obesity,' she said. 'But I'm overweight, and I could probably benefit from a GLP-1. Without clear weight-related indications, it's hard, perhaps to be able to justify prescribing it if it's not going to be available. So it's a hard conversation [for clinicians] to bring up with their patients.'
Yahoo
14 hours ago
- Yahoo
Parkinson's Disease Has a Smell That Some Dogs Can Detect
Dogs really can be trained to smell Parkinson's disease, according to new research from the United Kingdom. In a double blind trial, a Golden Retriever and a Labrador were able to sniff out which skin swabs came from people with Parkinson's. The smell of the oily secretions seemed to hold secret clues. "The dogs in this study achieved high sensitivity and specificity and showed there is an olfactory signature distinct to patients with the disease," says animal behavioral scientist Nicola Rooney from the University of Bristol. "Sensitivity levels of 70 percent and 80 percent are well above chance, and I believe that dogs could help us to develop a quick, non-invasive, and cost-effective method to identify patients with Parkinson's disease." Related: Today, there is no definitive early test for Parkinson's, which is why scientists are so interested in finding potential biomarkers of the disease on our skin. The knowledge that Parkinson's distinctly changes a person's body odor first came to light roughly a decade ago – all because of one woman. Twelve years before her husband's diagnosis of Parkinson's disease, Joy Milne could sense something was off – specifically, she could smell it. Milne, a Scottish nurse, is known as a 'super-smeller', and in 2016, she became famous among neuroscientists for her extraordinary abilities. In a small pilot study, Milne correctly identified each patient with Parkinson's disease based solely on the scent of their shirts. Her one misidentification turned out to be correct nearly a year later. The news raised an important question: If someone like Milne could smell Parkinson's years before it was diagnosed, could a dog do the same? Dogs are known to have incredible senses of smell, far more powerful than our own. Previous studies have found our pets can smell our stress, our coronavirus infections, and even our cancers – so if a distinct odor for Parkinson's does exist, then maybe a dog can sniff it out, too. In the past decade, a few preliminary trials have provided evidence for that hypothesis. But some only gave limited information on how the dogs were trained and tested. The recent trial from the UK is a collaboration between a program called Medical Detection Dogs and neuroscientists at the University of Manchester. One goal of the research is to figure out what the dogs are actually smelling, and why. In 2019, for instance, researchers at Manchester helped identify which odor compounds set the distinctive smell of Parkinson's apart. Their results were later confirmed by Milne, the serendipitous "super-smeller". A few years on, the odor compounds were used to create a diagnostic 'swab test' for Parkinson's, currently in testing. Perhaps, further down the road, trained dogs could help neuroscientists identify more unique biomarkers of the disease. The trouble is, though, not all canines are up to snuff. In the current trial, only 2 out of 10 dogs made it through training, and neither performed perfectly. One dog, for instance, falsely flagged a tenth of the odor swabs from healthy people as having Parkinson's. The other gave false alarms less than 2 percent of the time. Overall, however, the dogs could smell which person had Parkinson's at a rate well above chance, providing proof of principle. "We are extremely proud to say that once again, dogs can very accurately detect disease," says Claire Guest, the CEO of Medical Detection Dogs. "There is currently no early test for Parkinson's disease and symptoms may start up to 20 years before they become visible and persistent leading to a confirmed diagnosis. "Timely diagnosis is key… " The study was published in the Journal of Parkinson's Disease. Related News Expert Reveals What Can Happen if Testosterone Gel Rubs Onto Others Radioactive Waste Exposed Children in Missouri to Cancer Risks, Study Finds A Single Brain Scan Halfway Through Your Life Can Reveal How Fast You're Aging Solve the daily Crossword